CGPT fluctuates 40.6% in 24 hours: Pullback from highs, trading volume surges driven by AI narrative
Bitget Pulse2026/05/16 09:28Volatility Overview
CGPT’s price rapidly surged from a low of $0.03169 to a high of $0.04455 in the past 24 hours, before retreating to the current $0.03185, resulting in an overall swing of 40.6%. According to data from platforms such as CoinGecko, 24-hour trading volume saw a significant increase (some platforms reported over 70% growth), capital activity became notably more active, but there was no record of large-scale net inflows.
Brief Analysis of the Abnormal Fluctuation
- Trading Volume and Market Liquidity Driven: Trading volume across several platforms greatly increased within 24 hours (with some reporting gains of 72%-145%), reflecting the surge of short-term speculative trading, directly boosting price volatility.
- Ongoing AI Narrative: As an AI agent infrastructure project, ChainGPT was recently listed by CertiK Skynet as one of BNB Chain’s Top 10 AI Agents. Together with the CGPT token burn event (featuring reward pools and NFT incentives) currently being conducted by the official team, this has strengthened the community’s outlook for ecosystem development.
- No Single Major 24h Catalyst: Searches revealed no official announcements, large whale transfers, or on-chain anomalies acting as direct catalysts. The price movement mainly stems from broad AI sector sentiment and high-frequency trading activity.
Market Opinions and Outlook
The mainstream sentiment among the community and analysts is cautiously optimistic: long-term prospects are favorable for ChainGPT due to its progress in AI agents and the AIVM testnet, according to the roadmap. However, there are short-term warnings that a high RSI may trigger a pullback, with recommendations to monitor the $0.03 support level and whether trading volume persists. Some traders have mentioned that “low market cap AI tokens still have potential,” while also emphasizing risk management.
Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
